CUA Educational Content

Setting a New Standard for High-Risk Biochemical Recurrence in Prostate Cancer

Recording from June 30, 2024

Speakers: Brita Danielson, Tony Finelli & Christian Kollmannsberger

Objectives:

By participating in this learning program, healthcare providers can expect to gain an understanding of:

  • Review the latest evidence and discuss the optimal management for patients presenting with a high-risk biochemical recurrence (BCR) following surgery and/or radiation therapy for localized prostate cancer.
  • Discuss the challenges of incorporating androgen receptor pathway inhibitors (ARPIs) and prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging into the management of high-risk BCR.
Start Quiz for Credits

ACCREDITATION

This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by CUA. You may claim a maximum of 1 hour of credit.

This program has received financial support from Astellas in the form of an educational grant.

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy